Apertor Pharmaceuticals

Apertor Pharmaceuticals is a private, preclinical-stage biotech pioneering a novel approach to disrupt protein-protein interactions (PPIs) in oncology. Its core technology platform develops 'Interceptors,' heterobifunctional small molecules that recruit the abundant intracellular protein FKBP12 to sterically obstruct oncogenic signaling complexes, offering a differentiated mechanism from protein degraders like PROTACs. The company is advancing a pipeline led by a program targeting mTORC1/4E-BP1 in solid tumors and is backed by a team of experienced founders and scientific advisors with deep expertise in chemical biology and drug discovery.

Proprietary 'Interceptor' platform for developing heterobifunctional small molecules that induce proximity between an endogenous obstructor protein (e.g., FKBP12) and a target protein complex to sterically disrupt disease-causing protein-protein interactions (PPIs).

Apertor competes in the rapidly evolving field of proximity-inducing drugs, primarily against well-funded companies developing PROTACs (e.g., Arvinas, Nurix) and molecular glues. Its key differentiation is the focus on steric obstruction rather than degradation, which may allow targeting of a different subset of proteins but remains to be clinically validated.